Exentis Group

HardwareStetten, Aargau, SwitzerlandFounded 2013· One of 1756 Hardware companies tracked by AMPulse

Swiss pioneer of patented Additive Screen Printing technology enabling mass production of millions of precision micro-structured components (125 µm channel resolution) in metals, ceramics, polymers, and pharmaceutical materials on a single industrial platform — addressing the gap between conventional AM (low-volume) and traditional manufacturing (no geometric freedom).

CEO / Founder: Dr. Rolf Bachmann
Team Size: 51-200
Stage: Active
Total Funding: $17M

Technology & Products

Key Products

Exentis 3D Production Systems (industrial variant); Exentis Pharma cleanroom production systems (tablets with adjustable drug release profiles); Contract manufacturing services (AMaaS model); Application-specific licenses for exclusive customer verticals; Material pastes (metals, ceramics, polymers, pharma APIs, biomaterials); Part development project services

Technological Advantage

CLAIMED: 'world's only' industrialized AM technology for mass production at millions-of-parts scale; 125 µm channel resolution in metals and ceramics; multi-material processing (metals, ceramics, polymers, pharma) on one platform; 48-hour screen changeover for rapid geometry changes. VERIFIED: patents secured across critical aspects of 3D screen printing process (specific patent numbers not publicly disclosed in available sources); commercially validated at scale — CHF 14.1M H1 2024 revenue (+24% YoY), 23% EBITDA margin, $22.4M in US production system sales (Q4 2024); major 10-system order secured; pharmaceutical cleanroom system installed at Italian customer. DEFENSIBLE: patented process with application-specific exclusive licensing creates customer lock-in. REPLICABLE RISK: screen printing is a known industrial process; depth and breadth of patent portfolio determines true defensibility.

Differentiation

Value Proposition

Enables industrial and pharmaceutical OEMs to mass-produce millions of micro-structured components with 125 µm channel widths — geometries impossible with conventional AM — at production economics validated by CHF 14.1M H1 2024 revenue (+24% YoY) and 23% EBITDA margin; $22.4M in US production system sales (2024) confirms global demand; cold paste printing process eliminates material waste and allows geometry changes within 48 hours via new screen tooling.

How They Differentiate

Unlike Lithoz (ceramic-only DLP/LCM, limited to ceramics, batch production) and Desktop Metal/ExOne (single-material binder jetting, sintering-dependent accuracy), Exentis processes metals, ceramics, polymers, and pharma APIs on one unified platform; achieves 125 µm channel resolution at true mass-production volumes (millions of parts per year) vs. typical AM runs of 1–10,000 units; cold paste process avoids sintering shrinkage and distortion that limits binder jetting dimensional accuracy; 48-hour screen changeover for geometry changes enables mass customization at zero tooling lead time vs. weeks for metal injection molding or casting tooling; application-exclusive licensing model creates defensible customer relationships not available through equipment-only competitors.

Market & Competition

Target Customers

Industrial OEMs requiring mass production of micro-structured metal or ceramic components (hydraulic micro-filters, cooling channels, precision parts); pharmaceutical manufacturers needing high-volume tablets with freely adjustable drug release profiles; electronics, automotive, and medical device companies requiring fine-feature components at millions-of-parts scale

Industry Verticals

Industrial Manufacturing; Pharmaceuticals; Medical Devices; Electronics; Automotive; Aerospace

Competitors

Lithoz (high-precision ceramic AM systems for industrial production, LCM/DLP technology); Desktop Metal / ExOne (binder jetting for high-volume metal and ceramic component production at industrial scale)

Growth & Milestones

Growth Metrics

H1 2024 revenue: CHF 14.1M (+24% YoY); H1 2024 EBITDA margin: 23% (profitable at scale); US market 2024: $22.4M in production system sales; Q4 2024: 9 production systems sold to US customers; Major order secured for 10 additional production systems; US pipeline of ongoing projects expected to yield further development contracts, manufacturing orders, and purchase agreements; expanding from primarily European operations to global platform with US subsidiary established 2023

Major Milestones

Patented 3D screen printing (Additive Screen Printing) technology developed and commercialized; Exentis Pharma cleanroom production systems launched; 2023: Founded Exentis North America Inc. (US expansion); H1 2024: CHF 14.1M revenues (+24% YoY), EBITDA margin 23%; Q4 2024: Sold 9 Exentis production systems to US customers; 2024: Total US machine sales reached $22.4M across multiple customers; Secured major order for 10 additional production systems (large-scale industrial applications); Laxxon Medical–Hovione long-term pharmaceutical strategic cooperation announced; Restructured management with dedicated CCO (Michael Leitner) and CPO (Dr. Srdan Vasic) to accelerate market penetration; AGM 2024 attended by 120 shareholders

Notable Customers

Unnamed Italian pharmaceutical company (Exentis Pharma cleanroom production system installed for tablets with adjustable release profiles); multiple unnamed US industrial customers (9 production systems purchased Q4 2024; $22.4M in total US machine sales 2024)

https://www.exentis-group.com

Why this company matters

Exentis Group AG occupies a distinct niche in additive manufacturing, bridging the gap between low-volume AM and conventional mass production. Its patented Additive Screen Printing technology enables the fabrication of millions of precision micro-structured components per year, with channel widths as fine as 125 µm, across metals, ceramics, polymers, and pharmaceutical materials on a single industrial platform. This positions the company as a challenger in a self-defined category, validated by CHF 14.1M in H1 2024 revenue (+24% YoY) and a 23% EBITDA margin.

The core technology uses a cold paste printing process that deposits material through a screen, layer by layer, to build up three-dimensional structures. Unlike binder jetting or DLP, the cold process avoids sintering shrinkage and distortion, enabling tighter dimensional accuracy. Geometry changes can be implemented within 48 hours by swapping the screen tooling, offering mass customization with zero tooling lead time. The company offers two product lines: Exentis 3D Production Systems for industrial applications and Exentis Pharma cleanroom systems for pharmaceutical tablets with adjustable drug release profiles.

Target customers include industrial OEMs needing high-volume micro-structured metal or ceramic components—such as hydraulic micro-filters or cooling channels—and pharmaceutical manufacturers seeking scalable production of tablets with customized release kinetics. In 2024, Exentis sold 9 production systems to US customers, generating $22.4M in machine sales, and secured a major order for 10 additional systems. A pharmaceutical cleanroom system was installed at an unnamed Italian customer, and a strategic cooperation with Laxxon Medical and Hovione targets pharmaceutical AM production.

Exentis's strategic moat rests on its patented process and an application-specific exclusive licensing model that creates customer lock-in. While screen printing is a known industrial technique, the breadth of Exentis's patent portfolio—covering apparatus, screens, and applications—determines defensibility. Key competitors include Lithoz (ceramic DLP) and Desktop Metal/ExOne (binder jetting), but Exentis differentiates by processing multiple material classes on one platform at true mass-production volumes. The company's limited brand recognition outside Europe and reliance on a novel process category present risks, but its profitable growth and expanding US footprint signal institutional adoption.